Monthly Archives: January 2024

FDA’s OPDP Sends First Regulatory Letter of the Year Aimed at Rx Drug Promotion

Last week FDA’s Office of Prescription Drug Promotion issued its first regulatory action letter of the year. This was an Untitled Letter – a/k/a Notice of Violation Letter (NOV) – sent by the agency to Novartis in relation to promotional … Continue reading

Posted in Warning Letters | Tagged , , | Comments Off on FDA’s OPDP Sends First Regulatory Letter of the Year Aimed at Rx Drug Promotion